Bionano Genomics announced its participation at the Cancer Genomics Consortium, CGC, 2024 Annual Meeting with a broad range of content covering the utility of optical genome mapping, OGM, for hematological malignancy cancer research, including scientific poster presentations and an exhibitor session featuring data from a multi-site study evaluating OGM’s utility for evaluating hematological malignancies. CGC’s annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics for oncology research. CGC conference sessions will be held August 4-7, 2024, online and in-person in St. Louis, Missouri.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference
- Bionano Genomics announces publication of first multi-site study on OGM
- Bionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- BioNano Genomics Launches $10M Share & Warrant Offering
- Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules